Spots Global Cancer Trial Database for thyroid gland medullary carcinoma

Every month we try and update this database with for thyroid gland medullary carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer	NCT00005842	Cancer	trastuzumab tipifarnib	18 Years -	National Cancer Institute (NCI)
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors	NCT02867592	Adrenal Cortica... Alveolar Soft P... Central Nervous... Childhood Clear... Clear Cell Sarc... Ewing Sarcoma Hepatoblastoma Hepatocellular ... Osteosarcoma Recurrent Adren... Recurrent Alveo... Recurrent Clear... Recurrent Ewing... Recurrent Hepat... Recurrent Hepat... Recurrent Kidne... Recurrent Malig... Recurrent Osteo... Recurrent Prima... Recurrent Renal... Recurrent Rhabd... Recurrent Soft ... Recurrent Thyro... Refractory Adre... Refractory Alve... Refractory Clea... Refractory Ewin... Refractory Hepa... Refractory Hepa... Refractory Mali... Refractory Oste... Refractory Prim... Refractory Prim... Refractory Rena... Refractory Rhab... Refractory Soft... Refractory Thyr... Refractory Wilm... Renal Cell Carc... Rhabdomyosarcom... Soft Tissue Sar... Solid Neoplasm Thyroid Gland M... Wilms Tumor	Cabozantinib Cabozantinib S-... Pharmacological...	2 Years - 30 Years	National Cancer Institute (NCI)
NGR-TNF in Treating Patients With Advanced Solid Tumors	NCT00098943	Colorectal Canc... Head and Neck C... Kidney Cancer Unspecified Adu...	CNGRC peptide-T...	18 Years -	European Organisation for Research and Treatment of Cancer - EORTC
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer	NCT04759911	Malignant Thyro... Poorly Differen... Recurrent Thyro... Thyroid Gland A... Thyroid Gland M... Thyroid Gland P... Thyroid Gland S...	Quality-of-Life... Questionnaire A... Selpercatinib Therapeutic Con...	12 Years -	M.D. Anderson Cancer Center
Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy	NCT00095836	Head and Neck C...	Gefitinib	18 Years -	Massachusetts General Hospital
Iodine I 131 in Treating Patients With Thyroid Cancer	NCT00416949	Head and Neck C...	Patient-specifi...	18 Years - 100 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer	NCT00100828	Head and Neck C...	irinotecan hydr...	18 Years - 120 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases	NCT00062348	Colorectal Canc... Head and Neck C... Metastatic Canc...	boronophenylala... sodium borocapt... conventional su...	18 Years -	European Organisation for Research and Treatment of Cancer - EORTC
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors	NCT01709435	Recurrent Malig... Recurrent Melan... Recurrent Prima... Recurrent Thyro... Refractory Mali... Refractory Prim... Thyroid Gland M...	Cabozantinib S-... Laboratory Biom... Pharmacological...	2 Years - 18 Years	National Cancer Institute (NCI)
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors	NCT00002608	Adrenocortical ... Brain and Centr... Head and Neck C... Liver Cancer Malignant Mesot... Pheochromocytom... Sarcoma	cisplatin doxorubicin hyd... tamoxifen citra... conventional su... radiation thera...	- 65 Years	National Cancer Institute (NCI)
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors	NCT01155258	Extensive Stage... Hereditary Para... Male Breast Can... Malignant Parag... Metastatic Gast... Metastatic Pheo... Pancreatic Poly... Recurrent Breas... Recurrent Cervi... Recurrent Endom... Recurrent Gastr... Recurrent Islet... Recurrent Neuro... Recurrent Non-s... Recurrent Ovari... Recurrent Ovari... Recurrent Pheoc... Recurrent Prost... Recurrent Renal... Recurrent Small... Recurrent Uteri... Regional Gastro... Regional Pheoch... Stage III Cervi... Stage III Endom... Stage III Neuro... Stage III Ovari... Stage III Ovari... Stage III Prost... Stage III Renal... Stage III Uteri... Stage IIIA Brea... Stage IIIA Non-... Stage IIIB Brea... Stage IIIB Non-... Stage IIIC Brea... Stage IV Breast... Stage IV Endome... Stage IV Neuroe... Stage IV Non-sm... Stage IV Ovaria... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IV Uterin... Stage IVA Cervi... Stage IVB Cervi... Thyroid Gland M...	temsirolimus vinorelbine dit...	18 Years -	University of Southern California
Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer	NCT00027534	Breast Cancer Colorectal Canc... Gallbladder Can... Gastric Cancer Head and Neck C... Liver Cancer Ovarian Cancer Pancreatic Canc... Testicular Germ...	TRICOM-CEA(6D)	18 Years -	Duke University
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer	NCT00005842	Cancer	trastuzumab tipifarnib	18 Years -	National Cancer Institute (NCI)
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors	NCT01155258	Extensive Stage... Hereditary Para... Male Breast Can... Malignant Parag... Metastatic Gast... Metastatic Pheo... Pancreatic Poly... Recurrent Breas... Recurrent Cervi... Recurrent Endom... Recurrent Gastr... Recurrent Islet... Recurrent Neuro... Recurrent Non-s... Recurrent Ovari... Recurrent Ovari... Recurrent Pheoc... Recurrent Prost... Recurrent Renal... Recurrent Small... Recurrent Uteri... Regional Gastro... Regional Pheoch... Stage III Cervi... Stage III Endom... Stage III Neuro... Stage III Ovari... Stage III Ovari... Stage III Prost... Stage III Renal... Stage III Uteri... Stage IIIA Brea... Stage IIIA Non-... Stage IIIB Brea... Stage IIIB Non-... Stage IIIC Brea... Stage IV Breast... Stage IV Endome... Stage IV Neuroe... Stage IV Non-sm... Stage IV Ovaria... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IV Uterin... Stage IVA Cervi... Stage IVB Cervi... Thyroid Gland M...	temsirolimus vinorelbine dit...	18 Years -	University of Southern California
Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer	NCT00134043	Insular Thyroid... Recurrent Thyro... Stage II Follic... Stage II Papill... Stage IV Follic... Stage IV Papill... Thyroid Gland M...	vorinostat	18 Years -	National Cancer Institute (NCI)
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer	NCT00068497	Anaplastic Thyr... Insular Thyroid... Metastatic Para... Recurrent Adeno... Recurrent Basal... Recurrent Esthe... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Non-s... Recurrent Parat... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Thyro... Recurrent Verru... Stage III Folli... Stage III Papil... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Verru... Stage IIIB Non-... Stage IV Lympho... Stage IV Non-sm... Stage IV Squamo... Stage IV Squamo... Stage IVA Adeno... Stage IVA Basal... Stage IVA Esthe... Stage IVA Folli... Stage IVA Inver... Stage IVA Lymph... Stage IVA Midli... Stage IVA Mucoe... Stage IVA Papil... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Adeno... Stage IVB Basal... Stage IVB Esthe... Stage IVB Folli... Stage IVB Inver... Stage IVB Lymph... Stage IVB Midli... Stage IVB Mucoe... Stage IVB Papil... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Adeno... Stage IVC Basal... Stage IVC Esthe... Stage IVC Folli... Stage IVC Inver... Stage IVC Lymph... Stage IVC Midli... Stage IVC Mucoe... Stage IVC Papil... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Thryoid Gland N... Thyroid Gland M... Tongue Cancer Untreated Metas...	gefitinib	-	National Cancer Institute (NCI)
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors	NCT00019331	Colorectal Canc... Endometrial Can... Head and Neck C... Liver Cancer Lung Cancer Melanoma (Skin) Pancreatic Canc... Testicular Germ... Unspecified Adu...	aldesleukin ras peptide can... sargramostim DetoxPC	18 Years -	National Cancer Institute (NCI)
Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer	NCT01118065	Head and Neck C...	everolimus	18 Years -	National Cancer Institute (NCI)
Thalidomide in Treating Patients With Thyroid Cancer	NCT00026533	Head and Neck C...	thalidomide	18 Years - 120 Years	University of Kentucky
Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors	NCT00466856	Head and Neck C... Islet Cell Tumo... Metastatic Canc... Pheochromocytom...	octreotide acet... yttrium Y 90 re...	18 Years -	Vanderbilt-Ingram Cancer Center
NGR-TNF in Treating Patients With Advanced Solid Tumors	NCT00098943	Colorectal Canc... Head and Neck C... Kidney Cancer Unspecified Adu...	CNGRC peptide-T...	18 Years -	European Organisation for Research and Treatment of Cancer - EORTC
Iodine I 131 in Treating Patients With Thyroid Cancer	NCT00416949	Head and Neck C...	Patient-specifi...	18 Years - 100 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer	NCT00118248	Recurrent Thyro... Stage IV Follic... Stage IV Papill... Thyroid Gland M...	tanespimycin	18 Years -	National Cancer Institute (NCI)
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer	NCT02293954	Breast Cancer Colon Cancer Extrahepatic Bi... Gallbladder Can... Gastrointestina... Liver and Intra... Lung Cancer Metastatic Canc... Pancreatic Canc... Rectal Cancer Thyroid Gland M... Unspecified Adu...	radionuclide im... positron emissi... laboratory biom... pharmacological... Cu 64 anti-CEA ...	18 Years -	City of Hope Medical Center
Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy	NCT00095836	Head and Neck C...	Gefitinib	18 Years -	Massachusetts General Hospital
Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer	NCT00118248	Recurrent Thyro... Stage IV Follic... Stage IV Papill... Thyroid Gland M...	tanespimycin	18 Years -	National Cancer Institute (NCI)
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors	NCT01709435	Recurrent Malig... Recurrent Melan... Recurrent Prima... Recurrent Thyro... Refractory Mali... Refractory Prim... Thyroid Gland M...	Cabozantinib S-... Laboratory Biom... Pharmacological...	2 Years - 18 Years	National Cancer Institute (NCI)
Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients With Medullary Thyroid Cancer and Their Caregivers	NCT03892993	Thyroid Gland M...	Decision Aid Questionnaire A...	18 Years -	M.D. Anderson Cancer Center
SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck	NCT00005647	Head and Neck C...	paclitaxel semaxanib	18 Years -	Case Comprehensive Cancer Center
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer	NCT00068497	Anaplastic Thyr... Insular Thyroid... Metastatic Para... Recurrent Adeno... Recurrent Basal... Recurrent Esthe... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Non-s... Recurrent Parat... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Thyro... Recurrent Verru... Stage III Folli... Stage III Papil... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Verru... Stage IIIB Non-... Stage IV Lympho... Stage IV Non-sm... Stage IV Squamo... Stage IV Squamo... Stage IVA Adeno... Stage IVA Basal... Stage IVA Esthe... Stage IVA Folli... Stage IVA Inver... Stage IVA Lymph... Stage IVA Midli... Stage IVA Mucoe... Stage IVA Papil... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Adeno... Stage IVB Basal... Stage IVB Esthe... Stage IVB Folli... Stage IVB Inver... Stage IVB Lymph... Stage IVB Midli... Stage IVB Mucoe... Stage IVB Papil... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Adeno... Stage IVC Basal... Stage IVC Esthe... Stage IVC Folli... Stage IVC Inver... Stage IVC Lymph... Stage IVC Midli... Stage IVC Mucoe... Stage IVC Papil... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Thryoid Gland N... Thyroid Gland M... Tongue Cancer Untreated Metas...	gefitinib	-	National Cancer Institute (NCI)
Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer	NCT00134043	Insular Thyroid... Recurrent Thyro... Stage II Follic... Stage II Papill... Stage IV Follic... Stage IV Papill... Thyroid Gland M...	vorinostat	18 Years -	National Cancer Institute (NCI)
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer	NCT00096083	Cancer	isolated perfus... melphalan	16 Years -	Delcath Systems Inc.
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer	NCT04759911	Malignant Thyro... Poorly Differen... Recurrent Thyro... Thyroid Gland A... Thyroid Gland M... Thyroid Gland P... Thyroid Gland S...	Quality-of-Life... Questionnaire A... Selpercatinib Therapeutic Con...	12 Years -	M.D. Anderson Cancer Center
Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer	NCT01164176	Head and Neck C...	everolimus laboratory biom...	18 Years -	Yonsei University
Biological Therapy in Treating Patients With Metastatic Cancer	NCT00004604	Breast Cancer Colorectal Canc... Extrahepatic Bi... Gallbladder Can... Gastric Cancer Head and Neck C... Liver Cancer Lung Cancer Metastatic Canc... Ovarian Cancer Pancreatic Canc... Testicular Germ...	CEA RNA-pulsed ...	18 Years -	Duke University
Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer	NCT02592356	Differentiated ... Malignant Adren... Malignant Parag... Thyroid Gland M...	Computed Tomogr... Dual X-ray Abso... Physical Examin... Quality-of-Life... Questionnaire A... Cabozantinib Lenvatinib	18 Years -	M.D. Anderson Cancer Center
Radioimmunotherapy With or Without Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Thyroid Cancer	NCT00004048	Head and Neck C...	filgrastim doxorubicin hyd... autologous bone... peripheral bloo... indium In 111 m... yttrium Y 90 mo...	16 Years - 80 Years	Garden State Cancer Center at the Center for Molecular Medicine and Immunology

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: